ROCKVILLE, Md., April 13, 2016 /PRNewswire/ -- Therabron Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care, today announced that it has received Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent entitled "Modification and Compositions of Human Secretoglobin Proteins" (United States Patent Application No. 13/843,773). Scientific evidence supporting claims in this patent emanate from the development of novel isoforms of the Company's lead molecule, recombinant human CC10 (rhCC10). Similar patents, which also include several novel composition of matter claims, are being pursued in all major global markets.
"We continue to pursue a broad exclusivity strategy and this patent allowance further enhances a growing list of protections for our Recombinant Secretoglobin Platform," said Dr. Thomas F. Miller, Therabron's President and Chief Executive Officer. "In addition to our lead, hospital-based phase 2 program for CG100 in preterm infants, we are pursuing new development initiatives focused on ambulatory respiratory disease with confirmed deficiency in native CC10, including COPD. This patent provides the exclusivity required to pursue intervention in large ambulatory respiratory disease states with our portfolio of rhCC10 isoforms."
The Club cell 10kDa protein (CC10) is expressed by respiratory epithelial cells and plays an important protective role in healthy lungs by inhibiting multiple inflammatory pathways. Previous studies have identified that excessive inflammation in respiratory disease leads to important modifications of the native CC10 protein. Recently reported insights have enabled Therabron to develop new rhCC10 isoforms ex-vivo through simulation of chemical reactions that occur in respiratory inflammatory conditions in human biology.
About Therabron Therapeutics, Inc.
At Therabron Therapeutics, we are advancing a platform of novel therapeutic proteins in an effort to change how a variety of neglected and under-treated respiratory and fibrotic conditions are managed. We are a privately held, clinical-stage, biopharmaceutical company, developing a new class of drugs based on the naturally occurring secretoglobin family of proteins which includes the CC10 protein -- a molecule with both anti-inflammatory and immunomodulatory mechanisms. Therabron's product candidates have the potential to become first-in-class, biologic therapeutics. For additional information, please visit www.therabron.com.
SOURCE Therabron Therapeutics, Inc.